Durvalumab is a human anti-PD-L1 monoclonal antibody that is used to treat extensive-stage small cell lung cancer (ES-SCLC) in combination with etoposide and carboplatin or cisplatin (Table 1) [57]. This evidence concerns the gene CD274 and small cell lung carcinoma.